Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00582556 · ClinicalTrials.gov registry record · Phase 2
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 2
- Development phase
- 44
- Enrollment target
NCT00582556 is a Phase 2 study that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 44 participants.
The verdict
NCT00582556, a Phase 2 study, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 44 participants
- Enrollment target
Study Summary
The purpose of this research is to determine the effect of timing of Zometa® administration on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen deprivation therapy for prostate adenocarcinoma. In addition, the researchers will also determine the effects of treatment with Zometa® on peripheral blood markers of bone turnover, on peripheral blood gd T-cell frequencies and function, and to determine if the above treatments elicit prostate antigen-specific IgG immune responses. The effects of the above treatments on serial serum PSA measurements will also be examined.
Interventions
- DRUG Zometa
- DRUG zometa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2003-04 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00582556
The ClinicalTrials.gov registry entry for NCT00582556 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Zometa is the first listed.
NCT00582556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00582556 about?
NCT00582556 is a clinical study titled "Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy". The purpose of this research is to determine the effect of timing of Zometa® administration on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen deprivation therapy for prostate adenocarcinoma. In addition, the researchers will also determine the effects of treatme...
What is the current status of trial NCT00582556?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 44 participants. The study started on 2003-04. Estimated completion is 2013-03.
What interventions are being tested in trial NCT00582556?
The interventions under investigation include: Zometa (DRUG), zometa (DRUG).
Who is sponsoring clinical trial NCT00582556?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.